The Community of Madrid applies an innovative treatment for pancreatic cancer.
The pancreatic cancer has a new treatment Madrid’s communityconsisting of shrink the tumor for later removal. The objective of the specialists is that, in the medium term, it is possible to carry out their complete surgical removal. The novelty of this therapy is the use of a new radioactive isotopeadministered to a patient who has tolerated it without problem.
This initiative has been carried out in the Fuenlabrada public hospitalwithin the international registry Ospreya database that collects people diagnosed with this type of pathology and where they participate selected centers from different countries to study new treatments for pancreatic cancer.
The treatment has been approved by Spanish Agency for Medicines and Health Products (Aemps) and is already available to the National system of health (SNS). The new therapy consists of the use of brachytherapy con radiopharmaceuticalstechnique that through a endoscopy the active ingredient is injected into the tumor with highly controlled radiation. As stated by the head of the General Surgery and Digestive System Service at the University Hospital of Fuenlabrada, Fernando Pereiraprincipal investigator of the Osprey registry at this public health center in the region, are administered large doses with minimal toxicity.
In order to carry out the therapy efficiently and effectively, it has been necessary to coordination between different specialties of the hospital, which includes the services of Medical Oncology, Radiophysics, Digestive system, Nursing, Nuclear medicine y Radiology. Other professionals involved in the work carried out in this field are the head of the Radiophysics Service, Alfonso Lopez; oncologists Ignatius Judge y David Gutierrez; endoscopists Andrea Bermejo, Anthony Guardiola e Ivan War; Nuclear Medicine doctors Virginia Peiro, Pillar Buoy y Esther Llorente; and the radiologists Theresa Martin y Irrigation Covadonga.
A controlled radiation and chemotherapy treatment
“We have been the first in the world within the Osprey registry to apply it and it is very important for the entire team due to the synchronization that the entire Digestive Tumors Committee requires”, he explains. Virginia PeiroNuclear Medicine doctor at Fuenlabrada Hospital.
The injected radioisotope, Phosphorus 32comes to issue a beta radiationcausing the side effects sean minors and the tumor lesion can receive this controlled millimeter radiation for several months. “It is important to emphasize that the side effects are going to be small based on what has been described in the first studies and remember that this therapy is carried out in the Day Hospital, so that the patient does not require hospital admission and can go to house afterwards”, explains do Virginia Peiró.
Follow-up is then carried out in the usual way by the Medical Oncology Service. Patients who have undergone this new technique must continue with the chemotherapy treatment previously indicated, since both are complementary. This is the case of the first person who has received it at the Fuenlabrada Hospital, who has tolerated it without difficulty and continues with the usual chemotherapy.
Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any questions related to health be consulted with a health professional.